CompletedPhase 2Results posted

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial

Lead sponsor

Novo Nordisk A/S

Assets

Liraglutide / Semaglutide

Listed sites

Recruiting sites

Actual enrollment

415

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c 7-10%

Primary endpoint

•HbA1c, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00696657

Org study IDNN9535-1821

Secondary ID2007-003956-12

Timeline

Milestones

Study start2008-06-03actual

Study first posted2008-06-13estimated

Primary completion2009-02-05actual

Study completion2009-02-05actual

Results first posted2018-09-12actual

Last update posted2019-08-14actual

Assets

Investigational agents

Liraglutide Semaglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months

•Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months

•HbA1c: 7.0-10.0 % (both inclusive)

•Body weight between 60 kg and 110 kg

Exclusion criteria

•Treatment with insulin, GLP-1 receptor agonists (including liraglutide), dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, Alpha-GIs, or any investigational drug, within the last three months

•Impaired liver or kidney function

•Proliferative retinopathy or maculopathy requiring acute treatment

•Clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension

•Recurrent major hypoglycaemia or hypoglycaemic unawareness

•Present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)

Endpoints (70)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Cardiometabolic biomarkers

MASH / liver

Glycemic / diabetes

2 endpoints

Primary/registry result

HbA1c

Time frame:After 12 weeks of treatment.

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Mean · Percentage (%) of HbA1c	95% CI
Placebo	-0.5	-
Semaglutide 0.1 mg	-0.6	-
Semaglutide 0.2 mg	-0.9	-
Semaglutide 0.4 mg	-1.0	-
Semaglutide 0.8 mg	-1.4	-
Semaglutide 0.8 mg (With Titration)	-1.4	-
Semaglutide 1.6 mg (With Titration)	-1.5	-
Liraglutide 1.2 mg	-1.1	-
Liraglutide 1.8 mg	-1.3	-

Estimated treatment differences-1.1995% CI-1.58 - -0.80p<0.0001ANOVA

Estimated treatment differences-0.9595% CI-1.33 - -0.57p<0.0001ANOVA

Estimated treatment differences-0.9795% CI-1.35 - -0.59p<0.0001ANOVA

Estimated treatment differences-0.6195% CI-0.98 - -0.23p0.0002ANOVA

Estimated treatment differences-0.4195% CI-0.79 - -0.02p0.0324ANOVA

Estimated treatment differences-0.0995% CI-0.46 - 0.28p0.9772ANOVA

Estimated treatment differences-0.3595% CI-0.64 - -0.06ANOVA

Estimated treatment differences-0.1195% CI-0.39 - 0.18ANOVA

Estimated treatment differences-0.1395% CI-0.42 - 0.16ANOVA

Estimated treatment differences0.2495% CI-0.05 - 0.52ANOVA

Estimated treatment differences0.4495% CI0.15 - 0.73ANOVA

Estimated treatment differences0.7595% CI0.48 - 1.03ANOVA

Estimated treatment differences-0.8495% CI-1.12 - -0.56ANOVA

Estimated treatment differences-0.5195% CI-0.80 - -0.22ANOVA

Estimated treatment differences-0.2795% CI-0.56 - 0.02ANOVA

Estimated treatment differences-0.2995% CI-0.58 - 0.01ANOVA

Estimated treatment differences0.0895% CI-0.22 - 0.37ANOVA

Estimated treatment differences0.2895% CI-0.02 - 0.57ANOVA

Estimated treatment differences0.5995% CI0.31 - 0.88ANOVA

Estimated treatment differences-0.6895% CI-0.97 - -0.40ANOVA

Primary/protocol endpoint

HbA1c

Time frame:After 12 weeks of treatment.

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

4 endpoints

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; AST)

Time frame:Week 0, week 12.

AST, change

change from baseline, improvement

LOINC 1920-8

Posted result

Group	Mean · U/L	95% CI
Placebo	-1.09	-
Semaglutide 0.1 mg	1.23	-
Semaglutide 0.2 mg	0.24	-
Semaglutide 0.4 mg	-1.81	-
Semaglutide 0.8 mg	-0.37	-
Semaglutide 0.8 mg (With Titration)	-2.60	-
Semaglutide 1.6 mg (With Titration)	-4.07	-
Liraglutide 1.2 mg	-0.16	-
Liraglutide 1.8 mg	-2.13	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; ALAT)

Time frame:Week 0, week 12.

ALT, change

change from baseline, improvement

LOINC 1742-6

Posted result

Group	Mean · U/L	95% CI
Placebo	-2.41	-
Semaglutide 0.1 mg	0.83	-
Semaglutide 0.2 mg	0.68	-
Semaglutide 0.4 mg	-4.21	-
Semaglutide 0.8 mg	-2.13	-
Semaglutide 0.8 mg (With Titration)	-6.19	-
Semaglutide 1.6 mg (With Titration)	-6.55	-
Liraglutide 1.2 mg	-0.88	-
Liraglutide 1.8 mg	-1.83	-

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; AST)

Time frame:Week 0, week 12.

AST, change

change from baseline, improvement

LOINC 1920-8

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; ALAT)

Time frame:Week 0, week 12.

ALT, change

change from baseline, improvement

LOINC 1742-6

Cardiometabolic biomarkers

6 endpoints

Secondary/registry result

Change From Baseline in Vital Signs (Pulse)

Time frame:Week 0, week 12

Heart rate, change

change from baseline, improvement

Posted result

Group	Mean · Beats/minute	95% CI
Placebo	0.5	-
Semaglutide 0.1 mg	-0.0	-
Semaglutide 0.2 mg	0.5	-
Semaglutide 0.4 mg	1.5	-
Semaglutide 0.8 mg	1.5	-
Semaglutide 0.8 mg (With Titration)	2.9	-
Semaglutide 1.6 mg (With Titration)	3.9	-
Liraglutide 1.2 mg	4.4	-
Liraglutide 1.8 mg	2.1	-

Secondary/registry result

Change From Baseline in Vital Signs (Blood Pressure; SBP)

Time frame:Week 0, week 12

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Mean · mmHg	95% CI
Placebo	-3.2	-
Semaglutide 0.1 mg	3.3	-
Semaglutide 0.2 mg	-2.5	-
Semaglutide 0.4 mg	-3.6	-
Semaglutide 0.8 mg	-6.7	-
Semaglutide 0.8 mg (With Titration)	-7.7	-
Semaglutide 1.6 mg (With Titration)	-5.9	-
Liraglutide 1.2 mg	-2.9	-
Liraglutide 1.8 mg	-5.4	-

Secondary/registry result

Change From Baseline in Vital Signs (Blood Pressure; DBP)

Time frame:Week 0, week 12

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Mean · mmHg	95% CI
Placebo	-2.3	-
Semaglutide 0.1 mg	1.5	-
Semaglutide 0.2 mg	-0.4	-
Semaglutide 0.4 mg	-1.5	-
Semaglutide 0.8 mg	-1.5	-
Semaglutide 0.8 mg (With Titration)	-2.3	-
Semaglutide 1.6 mg (With Titration)	-3.0	-
Liraglutide 1.2 mg	-2.1	-
Liraglutide 1.8 mg	-0.0	-

Secondary/protocol endpoint

Change From Baseline in Vital Signs (Pulse)

Time frame:Week 0, week 12

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Vital Signs (Blood Pressure; SBP)

Time frame:Week 0, week 12

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change From Baseline in Vital Signs (Blood Pressure; DBP)

Time frame:Week 0, week 12

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Safety / tolerability / PK

58 endpoints

Secondary/registry result

Percentage of Subjects With an Adverse Events

Time frame:After 12 weeks of treatment.

Treatment-emergent AEs (any)

threshold achievement, event

Posted result

Group	Number · Percentage (%) of subjects	95% CI
Placebo	43.5	-
Semaglutide 0.1 mg	59.6	-
Semaglutide 0.2 mg	55.8	-
Semaglutide 0.4 mg	72.9	-
Semaglutide 0.8 mg	85.7	-
Semaglutide 0.8 mg (With Titration)	72.1	-
Semaglutide 1.6 mg (With Titration)	93.6	-
Liraglutide 1.2 mg	55.6	-
Liraglutide 1.8 mg	62.0	-

Secondary/registry result

Percentage of Subjects With Hypoglycaemic Episode

Time frame:After 12 weeks of treatment

Documented hypoglycemia

threshold achievement, event

Posted result

Group	Number · Percentage (%) of subjects	95% CI
PlaceboMajor	0	-
Minor	0	-
Symptoms only	2.2	-
Semaglutide 0.1 mgMajor	0	-
Minor	4.3	-
Symptoms only	2.1	-
Semaglutide 0.2 mgMajor	0	-
Minor	0	-
Symptoms only	2.3	-
Semaglutide 0.4 mgMajor	0	-
Minor	4.2	-
Symptoms only	0	-
Semaglutide 0.8 mgMajor	0	-
Minor	0	-
Symptoms only	0	-
Semaglutide 0.8 mg (With Titration)Major	0	-
Minor	2.3	-
Symptoms only	0	-
Semaglutide 1.6 mg (With Titration)Major	0	-
Minor	0	-
Symptoms only	6.4	-
Liraglutide 1.2 mgMajor	0	-
Minor	4.4	-
Symptoms only	8.9	-
Liraglutide 1.8 mgMajor	0	-
Minor	2.0	-
Symptoms only	2.0	-

Secondary/registry result

Change From Baseline in ECG

Time frame:Week 0, week 12.

categorical status, descriptive

Posted result

Group	Participants	95% CI
PlaceboWeek -2: Normal	42	-
Week -2: Abnormal, NCS	4	-
Week -2: Abnormal, CS	0	-
Week 12: Normal	39	-
Week 12: Abnormal, NCS	6	-
Week 12: Abnormal, CS	0	-
Week 12: ECG not done (ND)	1	-
Semaglutide 0.1 mgWeek -2: Normal	33	-
Week -2: Abnormal, NCS	14	-
Week -2: Abnormal, CS	0	-
Week 12: Normal	32	-
Week 12: Abnormal, NCS	14	-
Week 12: Abnormal, CS	0	-
Week 12: ECG not done (ND)	1	-
Semaglutide 0.2 mgWeek -2: Normal	37	-
Week -2: Abnormal, NCS	6	-
Week -2: Abnormal, CS	0	-
Week 12: Normal	34	-
Week 12: Abnormal, NCS	3	-
Week 12: Abnormal, CS	1	-
Week 12: ECG not done (ND)	5	-
Semaglutide 0.4 mgWeek -2: Normal	34	-
Week -2: Abnormal, NCS	12	-
Week -2: Abnormal, CS	2	-
Week 12: Normal	36	-
Week 12: Abnormal, NCS	7	-
Week 12: Abnormal, CS	2	-
Week 12: ECG not done (ND)	1	-
Semaglutide 0.8 mgWeek -2: Normal	31	-
Week -2: Abnormal, NCS	10	-
Week -2: Abnormal, CS	1	-
Week 12: Normal	29	-
Week 12: Abnormal, NCS	7	-
Week 12: Abnormal, CS	1	-
Week 12: ECG not done (ND)	3	-
Semaglutide 0.8 mg (With Titration)Week -2: Normal	28	-
Week -2: Abnormal, NCS	15	-
Week -2: Abnormal, CS	0	-
Week 12: Normal	33	-
Week 12: Abnormal, NCS	9	-
Week 12: Abnormal, CS	0	-
Week 12: ECG not done (ND)	1	-
Semaglutide 1.6 mg (With Titration)Week -2: Normal	37	-
Week -2: Abnormal, NCS	8	-
Week -2: Abnormal, CS	2	-
Week 12: Normal	36	-
Week 12: Abnormal, NCS	5	-
Week 12: Abnormal, CS	3	-
Week 12: ECG not done (ND)	2	-
Liraglutide 1.2 mgWeek -2: Normal	39	-
Week -2: Abnormal, NCS	6	-
Week -2: Abnormal, CS	0	-
Week 12: Normal	37	-
Week 12: Abnormal, NCS	6	-
Week 12: Abnormal, CS	0	-
Week 12: ECG not done (ND)	2	-
Liraglutide 1.8 mgWeek -2: Normal	41	-
Week -2: Abnormal, NCS	9	-
Week -2: Abnormal, CS	0	-
Week 12: Normal	42	-
Week 12: Abnormal, NCS	5	-
Week 12: Abnormal, CS	0	-
Week 12: ECG not done (ND)	2	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Basophils)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	-0.0	-
Semaglutide 0.1 mg	0.0	-
Semaglutide 0.2 mg	-0.0	-
Semaglutide 0.4 mg	0.0	-
Semaglutide 0.8 mg	-0.0	-
Semaglutide 0.8 mg (With Titration)	-0.0	-
Semaglutide 1.6 mg (With Titration)	-0.0	-
Liraglutide 1.2 mg	0.0	-
Liraglutide 1.8 mg	0.0	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Eosinophils)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	-0.0	-
Semaglutide 0.1 mg	0.0	-
Semaglutide 0.2 mg	-0.0	-
Semaglutide 0.4 mg	0.0	-
Semaglutide 0.8 mg	-0.0	-
Semaglutide 0.8 mg (With Titration)	0.0	-
Semaglutide 1.6 mg (With Titration)	0.1	-
Liraglutide 1.2 mg	0.0	-
Liraglutide 1.8 mg	-0.0	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haematocrit)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Litre/litre (L/L)	95% CI
Placebo	-0.01	-
Semaglutide 0.1 mg	-0.01	-
Semaglutide 0.2 mg	-0.01	-
Semaglutide 0.4 mg	0.00	-
Semaglutide 0.8 mg	-0.01	-
Semaglutide 0.8 mg (With Titration)	-0.00	-
Semaglutide 1.6 mg (With Titration)	-0.00	-
Liraglutide 1.2 mg	0.00	-
Liraglutide 1.8 mg	-0.01	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haemoglobin)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Gram/litre (g/L)	95% CI
Placebo	0.1	-
Semaglutide 0.1 mg	-0.4	-
Semaglutide 0.2 mg	-1.2	-
Semaglutide 0.4 mg	2.8	-
Semaglutide 0.8 mg	-0.3	-
Semaglutide 0.8 mg (With Titration)	1.5	-
Semaglutide 1.6 mg (With Titration)	1.0	-
Liraglutide 1.2 mg	2.1	-
Liraglutide 1.8 mg	1.1	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Lymphocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	-0.1	-
Semaglutide 0.1 mg	0.0	-
Semaglutide 0.2 mg	-0.1	-
Semaglutide 0.4 mg	0.2	-
Semaglutide 0.8 mg	-0.0	-
Semaglutide 0.8 mg (With Titration)	-0.1	-
Semaglutide 1.6 mg (With Titration)	0.1	-
Liraglutide 1.2 mg	0.0	-
Liraglutide 1.8 mg	-0.1	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Monocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	0.1	-
Semaglutide 0.1 mg	0.0	-
Semaglutide 0.2 mg	-0.0	-
Semaglutide 0.4 mg	0.1	-
Semaglutide 0.8 mg	0.1	-
Semaglutide 0.8 mg (With Titration)	0.0	-
Semaglutide 1.6 mg (With Titration)	0.1	-
Liraglutide 1.2 mg	0.1	-
Liraglutide 1.8 mg	0.1	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Neutrophils)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	0.1	-
Semaglutide 0.1 mg	0.0	-
Semaglutide 0.2 mg	-0.1	-
Semaglutide 0.4 mg	0.3	-
Semaglutide 0.8 mg	-0.1	-
Semaglutide 0.8 mg (With Titration)	0.5	-
Semaglutide 1.6 mg (With Titration)	0.5	-
Liraglutide 1.2 mg	0.3	-
Liraglutide 1.8 mg	0.3	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Thrombocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	9.0	-
Semaglutide 0.1 mg	16.1	-
Semaglutide 0.2 mg	10.8	-
Semaglutide 0.4 mg	10.7	-
Semaglutide 0.8 mg	5.4	-
Semaglutide 0.8 mg (With Titration)	5.5	-
Semaglutide 1.6 mg (With Titration)	15.9	-
Liraglutide 1.2 mg	10.1	-
Liraglutide 1.8 mg	16.7	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Erythrocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Trillion cells/litre (10^12/L)	95% CI
Placebo	-0.04	-
Semaglutide 0.1 mg	-0.06	-
Semaglutide 0.2 mg	-0.03	-
Semaglutide 0.4 mg	0.08	-
Semaglutide 0.8 mg	-0.05	-
Semaglutide 0.8 mg (With Titration)	0.03	-
Semaglutide 1.6 mg (With Titration)	0.04	-
Liraglutide 1.2 mg	0.04	-
Liraglutide 1.8 mg	0.02	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Leukocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Posted result

Group	Mean · Billion cells/litre (10^9/L)	95% CI
Placebo	0.05	-
Semaglutide 0.1 mg	0.04	-
Semaglutide 0.2 mg	-0.16	-
Semaglutide 0.4 mg	0.59	-
Semaglutide 0.8 mg	0.14	-
Semaglutide 0.8 mg (With Titration)	0.41	-
Semaglutide 1.6 mg (With Titration)	0.70	-
Liraglutide 1.2 mg	0.40	-
Liraglutide 1.8 mg	0.26	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Albumin)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · g/L	95% CI
Placebo	0.402	-
Semaglutide 0.1 mg	0.130	-
Semaglutide 0.2 mg	-0.091	-
Semaglutide 0.4 mg	-0.177	-
Semaglutide 0.8 mg	0.303	-
Semaglutide 0.8 mg (With Titration)	0.607	-
Semaglutide 1.6 mg (With Titration)	0.271	-
Liraglutide 1.2 mg	0.916	-
Liraglutide 1.8 mg	0.846	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Alkaline Phosphatase)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · U/L	95% CI
Placebo	-0.52	-
Semaglutide 0.1 mg	-1.66	-
Semaglutide 0.2 mg	-2.37	-
Semaglutide 0.4 mg	-2.35	-
Semaglutide 0.8 mg	-1.39	-
Semaglutide 0.8 mg (With Titration)	-2.81	-
Semaglutide 1.6 mg (With Titration)	-3.98	-
Liraglutide 1.2 mg	-1.89	-
Liraglutide 1.8 mg	-4.25	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Total Bilirubin)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · umol/L	95% CI
Placebo	0.7	-
Semaglutide 0.1 mg	-0.4	-
Semaglutide 0.2 mg	0.6	-
Semaglutide 0.4 mg	0.8	-
Semaglutide 0.8 mg	0.7	-
Semaglutide 0.8 mg (With Titration)	1.3	-
Semaglutide 1.6 mg (With Titration)	0.4	-
Liraglutide 1.2 mg	-0.5	-
Liraglutide 1.8 mg	0.2	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Total)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · mmol/L	95% CI
Placebo	0.0	-
Semaglutide 0.1 mg	-0.0	-
Semaglutide 0.2 mg	-0.0	-
Semaglutide 0.4 mg	-0.0	-
Semaglutide 0.8 mg	0.0	-
Semaglutide 0.8 mg (With Titration)	0.0	-
Semaglutide 1.6 mg (With Titration)	-0.0	-
Liraglutide 1.2 mg	-0.0	-
Liraglutide 1.8 mg	0.0	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Ionised)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · mmol/L	95% CI
Placebo	0.00	-
Semaglutide 0.1 mg	-0.01	-
Semaglutide 0.2 mg	-0.04	-
Semaglutide 0.4 mg	-0.01	-
Semaglutide 0.8 mg	-0.01	-
Semaglutide 0.8 mg (With Titration)	0.01	-
Semaglutide 1.6 mg (With Titration)	-0.02	-
Liraglutide 1.2 mg	-0.02	-
Liraglutide 1.8 mg	-0.01	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Creatinine)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · umol/L	95% CI
Placebo	-1.02	-
Semaglutide 0.1 mg	0.936	-
Semaglutide 0.2 mg	-0.349	-
Semaglutide 0.4 mg	-2.31	-
Semaglutide 0.8 mg	-0.658	-
Semaglutide 0.8 mg (With Titration)	-1.67	-
Semaglutide 1.6 mg (With Titration)	2.089	-
Liraglutide 1.2 mg	0.841	-
Liraglutide 1.8 mg	-0.917	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Potassium)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · mmol/L	95% CI
Placebo	0.07	-
Semaglutide 0.1 mg	0.08	-
Semaglutide 0.2 mg	0.06	-
Semaglutide 0.4 mg	-0.02	-
Semaglutide 0.8 mg	0.04	-
Semaglutide 0.8 mg (With Titration)	-0.02	-
Semaglutide 1.6 mg (With Titration)	-0.07	-
Liraglutide 1.2 mg	0.10	-
Liraglutide 1.8 mg	-0.12	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Sodium)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · mmol/L	95% CI
Placebo	0.1	-
Semaglutide 0.1 mg	0.0	-
Semaglutide 0.2 mg	-0.1	-
Semaglutide 0.4 mg	-0.1	-
Semaglutide 0.8 mg	0.4	-
Semaglutide 0.8 mg (With Titration)	0.2	-
Semaglutide 1.6 mg (With Titration)	0.5	-
Liraglutide 1.2 mg	0.7	-
Liraglutide 1.8 mg	0.6	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Urea)

Time frame:Week 0, week 12.

change from baseline, descriptive

Posted result

Group	Mean · mmol/L	95% CI
Placebo	-0.1	-
Semaglutide 0.1 mg	0.1	-
Semaglutide 0.2 mg	-0.1	-
Semaglutide 0.4 mg	-0.4	-
Semaglutide 0.8 mg	-0.3	-
Semaglutide 0.8 mg (With Titration)	-0.5	-
Semaglutide 1.6 mg (With Titration)	-0.5	-
Liraglutide 1.2 mg	-0.1	-
Liraglutide 1.8 mg	-0.4	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Glucose)

Time frame:Week 0, week 12

categorical status, descriptive

Posted result

Group	Participants	95% CI
PlaceboWeek 0: Negative	31	-
Week 0: Positive	13	-
Week 0: >=55 mmol/L	1	-
Week 0: Missing	1	-
Week 12: Negative	34	-
Week 12: Positive	8	-
Week 12: >=55 mmol/L	2	-
Week 12: Missing	0	-
Semaglutide 0.1 mgWeek 0: Negative	26	-
Week 0: Positive	18	-
Week 0: >=55 mmol/L	3	-
Week 0: Missing	0	-
Week 12: Negative	28	-
Week 12: Positive	15	-
Week 12: >=55 mmol/L	2	-
Week 12: Missing	1	-
Semaglutide 0.2 mgWeek 0: Negative	23	-
Week 0: Positive	15	-
Week 0: >=55 mmol/L	5	-
Week 0: Missing	0	-
Week 12: Negative	28	-
Week 12: Positive	8	-
Week 12: >=55 mmol/L	3	-
Week 12: Missing	2	-
Semaglutide 0.4 mgWeek 0: Negative	35	-
Week 0: Positive	11	-
Week 0: >=55 mmol/L	2	-
Week 0: Missing	0	-
Week 12: Negative	35	-
Week 12: Positive	8	-
Week 12: >=55 mmol/L	1	-
Week 12: Missing	1	-
Semaglutide 0.8 mgWeek 0: Negative	23	-
Week 0: Positive	15	-
Week 0: >=55 mmol/L	3	-
Week 0: Missing	0	-
Week 12: Negative	30	-
Week 12: Positive	2	-
Week 12: >=55 mmol/L	2	-
Week 12: Missing	3	-
Semaglutide 0.8 mg (With Titration)Week 0: Negative	28	-
Week 0: Positive	10	-
Week 0: >=55 mmol/L	3	-
Week 0: Missing	2	-
Week 12: Negative	39	-
Week 12: Positive	1	-
Week 12: >=55 mmol/L	0	-
Week 12: Missing	1	-
Semaglutide 1.6 mg (With Titration)Week 0: Negative	32	-
Week 0: Positive	12	-
Week 0: >=55 mmol/L	2	-
Week 0: Missing	1	-
Week 12: Negative	39	-
Week 12: Positive	3	-
Week 12: >=55 mmol/L	0	-
Week 12: Missing	1	-
Liraglutide 1.2 mgWeek 0: Negative	30	-
Week 0: Positive	10	-
Week 0: >=55 mmol/L	3	-
Week 0: Missing	2	-
Week 12: Negative	35	-
Week 12: Positive	7	-
Week 12: >=55 mmol/L	1	-
Week 12: Missing	0	-
Liraglutide 1.8 mgWeek 0: Negative	22	-
Week 0: Positive	20	-
Week 0: >=55 mmol/L	5	-
Week 0: Missing	3	-
Week 12: Negative	39	-
Week 12: Positive	6	-
Week 12: >=55 mmol/L	0	-
Week 12: Missing	2	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Haemoglobin)

Time frame:Week 0, week 12

categorical status, descriptive

Posted result

Group	Participants	95% CI
PlaceboWeek 0: Negative	45	-
Week 0: Trace	0	-
Week 0: Small	0	-
Week 0: Moderate	0	-
Week 0: Missing	1	-
Week 12: Negative	42	-
Week 12: Trace	0	-
Week 12: Small	1	-
Week 12: Large	1	-
Week 12: Missing	0	-
Semaglutide 0.1 mgWeek 0: Negative	45	-
Week 0: Trace	2	-
Week 0: Small	0	-
Week 0: Moderate	0	-
Week 0: Missing	0	-
Week 12: Negative	45	-
Week 12: Trace	0	-
Week 12: Small	0	-
Week 12: Large	0	-
Week 12: Missing	1	-
Semaglutide 0.2 mgWeek 0: Negative	41	-
Week 0: Trace	1	-
Week 0: Small	1	-
Week 0: Moderate	0	-
Week 0: Missing	0	-
Week 12: Negative	38	-
Week 12: Trace	1	-
Week 12: Small	0	-
Week 12: Large	0	-
Week 12: Missing	2	-
Semaglutide 0.4 mgWeek 0: Negative	45	-
Week 0: Trace	1	-
Week 0: Small	0	-
Week 0: Moderate	2	-
Week 0: Missing	0	-
Week 12: Negative	42	-
Week 12: Trace	2	-
Week 12: Small	0	-
Week 12: Large	0	-
Week 12: Missing	1	-
Semaglutide 0.8 mgWeek 0: Negative	38	-
Week 0: Trace	2	-
Week 0: Small	0	-
Week 0: Moderate	1	-
Week 0: Missing	0	-
Week 12: Negative	30	-
Week 12: Trace	1	-
Week 12: Small	2	-
Week 12: Large	1	-
Week 12: Missing	3	-
Semaglutide 0.8 mg (With Titration)Week 0: Negative	39	-
Week 0: Trace	1	-
Week 0: Small	1	-
Week 0: Moderate	0	-
Week 0: Missing	2	-
Week 12: Negative	38	-
Week 12: Trace	1	-
Week 12: Small	0	-
Week 12: Large	1	-
Week 12: Missing	1	-
Semaglutide 1.6 mg (With Titration)Week 0: Negative	43	-
Week 0: Trace	2	-
Week 0: Small	1	-
Week 0: Moderate	0	-
Week 0: Missing	1	-
Week 12: Negative	39	-
Week 12: Trace	2	-
Week 12: Small	1	-
Week 12: Large	0	-
Week 12: Missing	1	-
Liraglutide 1.2 mgWeek 0: Negative	43	-
Week 0: Trace	0	-
Week 0: Small	0	-
Week 0: Moderate	0	-
Week 0: Missing	2	-
Week 12: Negative	43	-
Week 12: Trace	0	-
Week 12: Small	0	-
Week 12: Large	0	-
Week 12: Missing	0	-
Liraglutide 1.8 mgWeek 0: Negative	45	-
Week 0: Trace	1	-
Week 0: Small	1	-
Week 0: Moderate	0	-
Week 0: Missing	3	-
Week 12: Negative	44	-
Week 12: Trace	1	-
Week 12: Small	0	-
Week 12: Large	0	-
Week 12: Missing	2	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Ketones)

Time frame:Week 0, week 12

descriptive

Posted result

Group	Participants	95% CI
PlaceboWeek 0: Negative	45	-
Week 0: Positive	0	-
Week 0: Missing	1	-
Week 12: Negative	43	-
Week 12: Positive	1	-
Week 12: Missing	0	-
Semaglutide 0.1 mgWeek 0: Negative	47	-
Week 0: Positive	0	-
Week 0: Missing	0	-
Week 12: Negative	44	-
Week 12: Positive	1	-
Week 12: Missing	1	-
Semaglutide 0.2 mgWeek 0: Negative	39	-
Week 0: Positive	4	-
Week 0: Missing	0	-
Week 12: Negative	35	-
Week 12: Positive	4	-
Week 12: Missing	2	-
Semaglutide 0.4 mgWeek 0: Negative	46	-
Week 0: Positive	2	-
Week 0: Missing	0	-
Week 12: Negative	44	-
Week 12: Positive	0	-
Week 12: Missing	1	-
Semaglutide 0.8 mgWeek 0: Negative	41	-
Week 0: Positive	0	-
Week 0: Missing	0	-
Week 12: Negative	34	-
Week 12: Positive	0	-
Week 12: Missing	3	-
Semaglutide 0.8 mg (With Titration)Week 0: Negative	41	-
Week 0: Positive	0	-
Week 0: Missing	2	-
Week 12: Negative	40	-
Week 12: Positive	0	-
Week 12: Missing	1	-
Semaglutide 1.6 mg (With Titration)Week 0: Negative	45	-
Week 0: Positive	1	-
Week 0: Missing	1	-
Week 12: Negative	38	-
Week 12: Positive	4	-
Week 12: Missing	1	-
Liraglutide 1.2 mgWeek 0: Negative	42	-
Week 0: Positive	1	-
Week 0: Missing	2	-
Week 12: Negative	41	-
Week 12: Positive	2	-
Week 12: Missing	0	-
Liraglutide 1.8 mgWeek 0: Negative	46	-
Week 0: Positive	1	-
Week 0: Missing	3	-
Week 12: Negative	43	-
Week 12: Positive	2	-
Week 12: Missing	2	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; pH)

Time frame:Week 0, week 12

descriptive

Posted result

Group	Participants	95% CI
PlaceboWeek 0: 6.0	16	-
Week 0: 6.5	13	-
Week 0: 7.0	11	-
Week 0: 7.5	4	-
Week 0: 8.0	0	-
Week 0: >=8.5	1	-
Week 0: Missing	1	-
Week 12: 6.0	11	-
Week 12: 6.5	15	-
Week 12: 7.0	15	-
Week 12: 7.5	3	-
Week 12: 8.0	0	-
Week 12: >=8.5	0	-
Week 12: Missing	0	-
Semaglutide 0.1 mgWeek 0: 6.0	13	-
Week 0: 6.5	18	-
Week 0: 7.0	12	-
Week 0: 7.5	3	-
Week 0: 8.0	0	-
Week 0: >=8.5	1	-
Week 0: Missing	0	-
Week 12: 6.0	14	-
Week 12: 6.5	14	-
Week 12: 7.0	13	-
Week 12: 7.5	2	-
Week 12: 8.0	1	-
Week 12: >=8.5	1	-
Week 12: Missing	1	-
Semaglutide 0.2 mgWeek 0: 6.0	19	-
Week 0: 6.5	15	-
Week 0: 7.0	8	-
Week 0: 7.5	0	-
Week 0: 8.0	1	-
Week 0: >=8.5	0	-
Week 0: Missing	0	-
Week 12: 6.0	19	-
Week 12: 6.5	9	-
Week 12: 7.0	6	-
Week 12: 7.5	4	-
Week 12: 8.0	1	-
Week 12: >=8.5	0	-
Week 12: Missing	2	-
Semaglutide 0.4 mgWeek 0: 6.0	11	-
Week 0: 6.5	21	-
Week 0: 7.0	10	-
Week 0: 7.5	5	-
Week 0: 8.0	1	-
Week 0: >=8.5	0	-
Week 0: Missing	0	-
Week 12: 6.0	9	-
Week 12: 6.5	14	-
Week 12: 7.0	11	-
Week 12: 7.5	7	-
Week 12: 8.0	2	-
Week 12: >=8.5	1	-
Week 12: Missing	1	-
Semaglutide 0.8 mgWeek 0: 6.0	10	-
Week 0: 6.5	13	-
Week 0: 7.0	12	-
Week 0: 7.5	5	-
Week 0: 8.0	0	-
Week 0: >=8.5	0	-
Week 0: Missing	1	-
Week 12: 6.0	10	-
Week 12: 6.5	7	-
Week 12: 7.0	11	-
Week 12: 7.5	3	-
Week 12: 8.0	2	-
Week 12: >=8.5	1	-
Week 12: Missing	3	-
Semaglutide 0.8 mg (With Titration)Week 0: 6.0	11	-
Week 0: 6.5	13	-
Week 0: 7.0	8	-
Week 0: 7.5	8	-
Week 0: 8.0	0	-
Week 0: >=8.5	1	-
Week 0: Missing	2	-
Week 12: 6.0	8	-
Week 12: 6.5	10	-
Week 12: 7.0	15	-
Week 12: 7.5	5	-
Week 12: 8.0	1	-
Week 12: >=8.5	1	-
Week 12: Missing	1	-
Semaglutide 1.6 mg (With Titration)Week 0: 6.0	14	-
Week 0: 6.5	10	-
Week 0: 7.0	12	-
Week 0: 7.5	7	-
Week 0: 8.0	3	-
Week 0: >=8.5	0	-
Week 0: Missing	1	-
Week 12: 6.0	13	-
Week 12: 6.5	11	-
Week 12: 7.0	10	-
Week 12: 7.5	5	-
Week 12: 8.0	1	-
Week 12: >=8.5	2	-
Week 12: Missing	1	-
Liraglutide 1.2 mgWeek 0: 6.0	8	-
Week 0: 6.5	16	-
Week 0: 7.0	14	-
Week 0: 7.5	3	-
Week 0: 8.0	2	-
Week 0: >=8.5	0	-
Week 0: Missing	2	-
Week 12: 6.0	9	-
Week 12: 6.5	13	-
Week 12: 7.0	16	-
Week 12: 7.5	4	-
Week 12: 8.0	0	-
Week 12: >=8.5	1	-
Week 12: Missing	0	-
Liraglutide 1.8 mgWeek 0: 6.0	12	-
Week 0: 6.5	11	-
Week 0: 7.0	19	-
Week 0: 7.5	2	-
Week 0: 8.0	1	-
Week 0: >=8.5	2	-
Week 0: Missing	3	-
Week 12: 6.0	10	-
Week 12: 6.5	14	-
Week 12: 7.0	15	-
Week 12: 7.5	3	-
Week 12: 8.0	2	-
Week 12: >=8.5	1	-
Week 12: Missing	2	-

Secondary/registry result

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Protein)

Time frame:Week 0, week 12

categorical status, descriptive

Posted result

Group	Participants	95% CI
PlaceboWeek 0: Negative	45	-
Week 0: 0.3	0	-
Week 0: 1.0	0	-
Week 0: Missing	1	-
Week 12: Negative	40	-
Week 12: Trace	0	-
Week 12: 0.3	4	-
Week 12: 1.0	0	-
Week 12: >=3.0	0	-
Week 12: Missing	0	-
Semaglutide 0.1 mgWeek 0: Negative	47	-
Week 0: 0.3	0	-
Week 0: 1.0	0	-
Week 0: Missing	0	-
Week 12: Negative	43	-
Week 12: Trace	0	-
Week 12: 0.3	2	-
Week 12: 1.0	0	-
Week 12: >=3.0	0	-
Week 12: Missing	1	-
Semaglutide 0.2 mgWeek 0: Negative	41	-
Week 0: 0.3	2	-
Week 0: 1.0	0	-
Week 0: Missing	0	-
Week 12: Negative	35	-
Week 12: Trace	0	-
Week 12: 0.3	3	-
Week 12: 1.0	1	-
Week 12: >=3.0	0	-
Week 12: Missing	2	-
Semaglutide 0.4 mgWeek 0: Negative	44	-
Week 0: 0.3	4	-
Week 0: 1.0	0	-
Week 0: Missing	0	-
Week 12: Negative	41	-
Week 12: Trace	0	-
Week 12: 0.3	3	-
Week 12: 1.0	0	-
Week 12: >=3.0	0	-
Week 12: Missing	1	-
Semaglutide 0.8 mgWeek 0: Negative	39	-
Week 0: 0.3	2	-
Week 0: 1.0	0	-
Week 0: Missing	0	-
Week 12: Negative	31	-
Week 12: Trace	0	-
Week 12: 0.3	3	-
Week 12: 1.0	0	-
Week 12: >=3.0	0	-
Week 12: Missing	3	-
Semaglutide 0.8 mg (With Titration)Week 0: Negative	40	-
Week 0: 0.3	0	-
Week 0: 1.0	1	-
Week 0: Missing	2	-
Week 12: Negative	36	-
Week 12: Trace	0	-
Week 12: 0.3	3	-
Week 12: 1.0	1	-
Week 12: >=3.0	0	-
Week 12: Missing	1	-
Semaglutide 1.6 mg (With Titration)Week 0: Negative	46	-
Week 0: 0.3	0	-
Week 0: 1.0	0	-
Week 0: Missing	1	-
Week 12: Negative	39	-
Week 12: Trace	1	-
Week 12: 0.3	2	-
Week 12: 1.0	0	-
Week 12: >=3.0	0	-
Week 12: Missing	1	-
Liraglutide 1.2 mgWeek 0: Negative	41	-
Week 0: 0.3	2	-
Week 0: 1.0	0	-
Week 0: Missing	2	-
Week 12: Negative	40	-
Week 12: Trace	0	-
Week 12: 0.3	1	-
Week 12: 1.0	1	-
Week 12: >=3.0	1	-
Week 12: Missing	0	-
Liraglutide 1.8 mgWeek 0: Negative	45	-
Week 0: 0.3	1	-
Week 0: 1.0	1	-
Week 0: Missing	3	-
Week 12: Negative	41	-
Week 12: Trace	0	-
Week 12: 0.3	3	-
Week 12: 1.0	1	-
Week 12: >=3.0	0	-
Week 12: Missing	2	-

Secondary/registry result

Change From Baseline in Calcitonin

Time frame:Week 0, week 12.

Thyroid event

change from baseline, descriptive

Posted result

Group	Mean · ng/L	95% CI
Placebo	0.43	-
Semaglutide 0.1 mg	0.48	-
Semaglutide 0.2 mg	-0.48	-
Semaglutide 0.4 mg	0.62	-
Semaglutide 0.8 mg	0.45	-
Semaglutide 0.8 mg (With Titration)	0.87	-
Semaglutide 1.6 mg (With Titration)	0.76	-
Liraglutide 1.2 mg	0.55	-
Liraglutide 1.8 mg	0.01	-

Secondary/registry result

Percentage of Subjects Developing Anti-semaglutide Antibodies

Time frame:After 12 weeks of treatment

Immunogenicity (ADA)

threshold achievement, event

Posted result

Group	Number · Percentage (%) of participants	95% CI
Placebo	0	-
Semaglutide 0.1 mg	0	-
Semaglutide 0.2 mg	0	-
Semaglutide 0.4 mg	0	-
Semaglutide 0.8 mg	0	-
Semaglutide 0.8 mg (With Titration)	0	-
Semaglutide 1.6 mg (With Titration)	3	-

Secondary/protocol endpoint

Percentage of Subjects With an Adverse Events

Time frame:After 12 weeks of treatment.

Treatment-emergent AEs (any)

threshold achievement, event

Secondary/protocol endpoint

Percentage of Subjects With Hypoglycaemic Episode

Time frame:After 12 weeks of treatment

Documented hypoglycemia

threshold achievement, event

Secondary/protocol endpoint

Change From Baseline in ECG

Time frame:Week 0, week 12.

categorical status, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Basophils)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Eosinophils)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haematocrit)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Haemoglobin)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Lymphocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Monocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Neutrophils)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Thrombocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Erythrocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Haematology; Leukocytes)

Time frame:Week 0, week 12

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Albumin)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Alkaline Phosphatase)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Total Bilirubin)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Total)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Calcium, Ionised)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Creatinine)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Potassium)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Sodium)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Biochemistry; Urea)

Time frame:Week 0, week 12.

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Glucose)

Time frame:Week 0, week 12

descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Haemoglobin)

Time frame:Week 0, week 12

descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Ketones)

Time frame:Week 0, week 12

categorical status, descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; pH)

Time frame:Week 0, week 12

descriptive

Secondary/protocol endpoint

Change From Baseline in Standard Safety Laboratory Parameter (Urinalysis; Protein)

Time frame:Week 0, week 12

categorical status, descriptive

Secondary/protocol endpoint

Change From Baseline in Calcitonin

Time frame:Week 0, week 12.

Thyroid event

change from baseline, event

Secondary/protocol endpoint

Percentage of Subjects Developing Anti-semaglutide Antibodies

Time frame:After 12 weeks of treatment

Immunogenicity (ADA)

threshold achievement, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Diabetes care2016 Feb (month)PMID26358288doi:10.2337/dc15-0165via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.